Dr Olivier Casasnovas, from the Department of Hematology, Dijon, France, gives an update on data from the Phase III AHL2011 study (NCT01358747). Dr Casanovas highlights the outstanding disease control results observed with a minimized BEACOPP exposure and toxicity in patients with advanced Hodgkin lymphoma. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.
